文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

轻度WAS/XLT患者的合并症需终身随访并考虑根治性治疗

Comorbidities in Mild WAS/XLT Require Lifelong Follow-Up and Consideration of Definitive Treatment.
PubMed 文献 · Am J Hematol · 2025-09-08

该研究基于法国国家原发性免疫缺陷参考中心登记处数据,分析了261例WAS/XLT患者中170例轻度患者的资料。轻度WAS患者40年总生存率为73%,严重WAS患者为65%(p=0.43)。轻度患者中38.2%在2岁后WAS严重度评分进展至4-5分;2010年以来45例造血干细胞移植无死亡报告。研究支持对所有患者(包括轻度型)在可行时进行根治性治疗。

要点

  • 轻度WAS/XLT患者2岁后仍有38.2%进展至WAS严重度评分4-5分。
  • 轻度WAS患者40年总生存率73%,严重WAS患者65%(p=0.43)。
  • 2010年以来45例HSCT无死亡报告,中位随访3.2年。

核心结论

  • 由于并发症可终生发生,本研究支持对所有患者(包括轻度型)在可行时进行根治性治疗。

研究设计与样本

  • 分析法国国家原发性免疫缺陷参考中心登记处WAS/XLT患者数据,截至2021年12月10日共261例患者,其中170例为轻度WAS/XLT。
  • 轻度WAS/XLT患者末次随访中位年龄15.8岁(范围2.0-60.4)。

主要发现

  • 轻度WAS患者40年总生存率为73%,严重WAS患者为65%(p=0.43)。
  • 轻度WAS患者中,在造血干细胞移植或基因治疗前,38.2%的患者在2岁后WAS严重度评分进展至4-5分。
  • 2010年以来共进行45例HSCT,无论初始严重度、移植类型、HLA相容性及诊断年龄,均无死亡报告,移植后中位随访3.2年(0-11.5)。

关键数值与推荐

  • 通常2岁时WAS临床严重度评分≤3分被认为属于轻度WAS/XLT。
  • 轻度WAS患者40年总生存率73% vs 严重WAS患者65%(p=0.43)。
  • 轻度WAS患者2岁后进展至WAS严重度评分4-5分的比例为38.2%。
  • 2010年以来45例HSCT无死亡报告,移植后中位随访3.2年(0-11.5)。

临床怎么用

  • 作者认为,由于并发症可终生发生,本研究支持对所有患者(包括轻度型)在可行时进行根治性治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Loss of function mutations in the gene encoding WASP (Wiskott-Aldrich syndrome protein) result in Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia-XLT (WAS/XLT). The clinical severity of the disease can be assessed using the WAS clinical severity score. Typically, patients with a score of 3 or less at 2 years of age are considered to have mild WAS/XLT disease. However, patients with a low score in the first 2 years of life can still experience life-threatening complications, and there are no agreed guidelines for the management of these patients with mild WAS/XLT. We analyzed data on WAS/XLT patients from the French National Reference Centre for Primary Immunodeficiencies registry. At 10 December 2021, data were available for 261 patients, 170 of whom had mild WAS/XLT. The median age of these patients at last follow-up was 15.8 years (range 2.0-60.4). Overall survival at 40 years was 73% in mild WAS patients versus 65% in severe WAS patients (p = 0.43). In the mild WAS population, prior to Hematopoietic Stem Cell Transplantation or gene therapy, 38.2% of patients progressed to a WAS severity score of 4-5 after the age of 2. Remarkably, no deaths were reported in 45 HSCTs performed since 2010, regardless of initial severity, type and HLA compatibility of the transplant, and age at diagnosis, with a median follow-up of 3.2 years (0-11.5) after transplant. As complications can occur throughout life, our study supports definitive treatment for all patients when available, including those with mild forms.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mallebranche C, Miot C, Alligon M, et al. Comorbidities in Mild WAS/XLT Require Lifelong Follow-Up and Consideration of Definitive Treatment. Am J Hematol. 2025. PMID: 40919766. doi:10.1002/ajh.70061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。